National Institute for Health and Care Excellence

Draft for consultation

Ovarian cancer: identifying and managing familial and genetic risk

NICE developer team staff list and expert witnesses

NICE guideline tbc Supplementary material 3 September 2023

Draft for Consultation

Supplementary material was developed by NICE



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to Notice of Rights.

ISBN:

DRAFT FOR CONSULTATION

Contents

NICE developer team staff list	. 2
Expert witness list	. 3

NICE developer team staff list

NGA staff:	Role:	Start Date:	End Date:
Laura Berg	Systematic Reviewer	March 2022	Present
Nathan Bromham	Senior Systematic Reviewer	July 2021	June 2023
Meleshah Brown	Business Administrator	July 2021	September 2021
Emma Clegg	Information Scientist	March 2022	Present
Katharina Dworzynski	Guideline Lead	July 2021	Present
Jen Francis	Business Administrator	October 2021	Present
Suhayl Kassam	Systematic Reviewer	September 2021	Present
Katriona O'Donoghue	Systematic Reviewer	August 2022	December 2022
Steve Pilling	Clinical Advisor	July 2021	Present
Timothy Reeves	Information Scientist	July 2021	March 2022
Neil Ryan	Clinical Fellow	October 2021	Present
Mia Schmidt-Hansen	Senior Systematic Reviewer	June 2023	Present
Hayley Shaw	Project Manager	July 2021	Present
Eric Slade	Senior Health Economist	July 2021	Present
Sarah Stockton	Information Scientist	July 2021	April 2022
Georgina Winney	Business Administrator	September 2021	October 2021

Expert witness list

Name	Affiliation	Review topic
Alistair McGuire	London School of Economics	Evidence review K – Benefits and risks of surveillance
Xia Wei	London School of Hygiene and Tropical Medicine and Queen Mary University of London	Evidence review N – Risk reducing surgery
Rosa Legood	London School of Hygiene and Tropical Medicine and Queen Mary University of London	Evidence review N – Risk reducing surgery

Additional support was received from: Georgina Winney (Business Administrator), Timothy Reeves (Guideline Lead), Angela Bennett (Director of Guidelines)